Background
Colorectal cancer (CRC) ranks third and second in morbidity and mortality, respectively [
1], which is a heavy burden on global health and medical services. Approximately 50% of CRC patients will suffer distant metastasis at a certain time in the course of the disease [
2]. Once this occurs, the prognosis of patients will be significantly deteriorated. Surgical intervention is still considered to be the most effective way to cure CRC patients with metastasis. Therefore, resection of the primary and metastatic lesions becomes the standard surgical procedure to improve the prognosis of CRC patients with metastasis [
3,
4]. However, the management of CRC patients with para-aortic lymph node metastasis (PALNM) remains controversial in the gastrointestinal surgical field for the tricky definition of these patients’ clinical stage. In 2019, the Japanese Society for Cancer of the Colon and Rectum (JSCCR) adjusted the staging of PALNM to four stages, which is consistent with the eighth edition of the Joint American Council on Cancer (AJCC) cancer staging, implying a constant updating and evolution of surgeons’ perceptions [
5‐
7].
The controversy regarding PALMN is mainly focused on the necessity and feasibility of the surgical resection, although there have been numerous studies with positive results [
8,
9]. AJCC considers that PALNM represents disseminated metastasis and should be classified as stage IV disease. While Japanese experts tended to classify PALNM as a regional, stage III disease. As for China, there were no unified diagnosis and treatment standard or expert guidelines for PALNM treatment so far. Given such various views on the management of PALNM, no wonder there are controversies on the choice of the optimal treatment approach for CRC patients with PALNM. Currently, the need for radical lymphadenectomy in CRC patients with PALNM largely depends on the surgeons’ occupational preference. To the best of our knowledge, no randomized controlled trials (RCTs) have been reported on CRC patients with PALNM worldwide. Moreover, although a number of cohort studies and case–control studies have been published with promising conclusions regarding the management of PALNM, the clinical characteristics of these studies, such as retrospective and small sample sizes, greatly limited their level of evidence-based medicine. In view of the controversy over treatment strategies about PALNM, it is particularly significant to conduct a systematic analysis of existing studies to form a relatively unified guidance scheme and provide professional reference for gastrointestinal surgeons.
Methods
Search strategy
A comprehensive literature search of PubMed, Embase and Cochrane Library irrespective of languages was conducted for research related to the management of CRC with PALNM up to 31 October 2021. We conceived a strategy that combined exploded medical subject heading (MeSH) terms and entry terms, and the terms were as follows: “Colorectal Neoplasms”, “Colorectal Neoplasm”, “Neoplasm, Colorectal”, “Colorectal Carcinoma”, “Carcinoma, Colorectal”, “Carcinomas, Colorectal”, “Colorectal Carcinomas”, “Colorectal Cancer”, “Cancer, Colorectal”, “Cancers, Colorectal”, “Colorectal Cancers”, “Colorectal Tumors”, “Colorectal Tumor”, “Tumor, Colorectal”, “Tumors, Colorectal”, “Neoplasms, Colorectal”, “Lymphatic Metastases”, “Lymph Node Metastasis”, “Lymph Node Metastases”, “Metastasis, Lymph Node”, “para-aortic” and “paraaortic”. Meanwhile, we identified and included some studies by screening the reference lists of similar reviews or systematic reviews. The current study was conducted in conformity to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statements [
10].
Inclusion and exclusion criteria
The inclusion criteria were as follows: (1) the studies comparing the efficacy and safety of radical lymphadenectomy with those not undergoing lymphadenectomy or radical lymphadenectomy among adult CRC patients with PALNM; (2) all included patients in the study must have clear preoperative imaging data and postoperative pathology reports to confirm PALNM.
The exclusion criteria included: (1) CRC patients with distant organs metastases; (2) CRC patients with other non-regional lymph nodes metastases rather than PALNM; (3) the studies had no control groups; (4) ongoing clinical trials; (5) lack of sufficient information or without follow-up.
Two reviewers independently screened and identified all potentially included studies. In the process of inclusion and exclusion, titles and abstracts were first checked, any conflicts between two reviewers were resolved by the third reviewer to achieve consensus. When the screening process of titles and abstracts was finished, full-text was subsequently assessed to determine its eligibility.
Data extraction and quality evaluation
The data from all eligible studies was independently extracted by reviewers with a standardized and predesigned table. The characteristics of eligible studies including first author, publication year, study type, total number of enrolled patients, intervention and comparison, primary outcomes etc. were recorded. Moreover, the inconsistency of extracted data was resolved by discussion or consulting another reviewer until a consensus was achieved.
We also assessed the risk of bias of each eligible study according to its study type. The quality of observational study (cohort study and case–control study) was judged using the Risk of Bias in Non-randomized Studies—of Interventions (ROBINS-I) tool. The ROBINS-I tool assesses bias across seven domains including: confounding, selection of participants, classification of interventions, deviations from intended interventions, missing data, measurement of outcomes and selection of reported results. For each domain an outcome of low, moderate, serious, critical and no information for risk of bias is recorded. An overall risk of bias judgement is then determined through combination of the above seven domains [
11].
Outcome measurements
Considering the generalization of overall survival (OS) in determining the prognosis of cancer patients, we chose OS as primary endpoint regardless of the follow-up time. For research purposes, 3-year or 5-year OS was acceptable. Besides, OS was preferentially reported by majority of included studies. The secondary endpoint was the rate of adverse reactions, which could reflect the safety of treatment. In addition, we performed a sensitivity analysis that excluded every study, each at a given time, to prove whether our conclusions were stable [
12].
Statistical analysis
Review Manager (RevMan 5.3, Copenhagen: the Nordic Cochrane Center, the Cochrane Collaboration, 2014) was used to conduct the current Meta-analysis. Odds ratios (ORs) were applied for dichotomous outcomes, and pooled proportions were calculated with 95% confidence intervals (95% CI). The heterogeneity of each outcome was evaluated by calculating the I2 statistic. The I2 > 50% indicated a significant heterogeneity and random effects model was applied, otherwise fixed effects model was used accordingly. In addition, we constructed the Funnel plot that could be visually inspected to assess the publication bias. Meanwhile, both Begg’s and Egger’s tests were conducted and a two-sided P-value < 0.05 was considered as statistically significance. In order to seek potential factors that could influence the heterogeneity, we performed subgroup analysis according to various subgroup standards, which was conductive to validating the consistency and robustness of our finding. To be specific, all eligible clinical studies were stratified by type of study (cohort study or case–control study), management (dissection or R0 resection), timing of metastasis (synchronous or metachronous), publication country (Korea or Japan) and location of primary tumors (left-sided or all).
Discussion
Para-aortic lymph node involvement in CRC is rare, with a reported incidence of less than 2% [
13,
14]. Unfortunately, the prognosis of CRC patients with PALNM is extremely poor. Therefore, a standardized treatment regimen worldwide is essential to improve the long-term survival of these patients. Currently, the efficacy of surgical resection and treatment of CRC patients with PALNM are still controversial. In this systematic review and meta-analysis, we evaluated the clinical efficacy and safety of radical lymphadenectomy in these patients. We were pleasant to find that radical lymphadenectomy could significantly improve the 5-year OS of CRC patients with PALNM. Moreover, we observed that radical lymphadenectomy had no additional effect on the incidence of postoperative complications compared with the control group. In order to explore the stability of the conclusion, we performed subgroup analysis according to various characteristics of eligible studies although these studies did not show significant heterogeneity. The subgroup analysis showed that the conclusions we had previously reached were quite stable, whether it was based on the type of study, the treatment strategy, the time of lymph node metastasis, or the nationality of the investigator and the location of the primary tumors.
In the past few decades, there have been several retrospective cohort studies and case–control studies [
15‐
19] conducted to explore the effectiveness of radical lymphadenectomy in improving prognosis of CRC patients with PALNM. However, these studies had limited evidence since most of them were retrospective studies with small samples. To date, no prospective RCTs have been reported on the clinical efficacy of radical lymphadenectomy in CRC patients with PALNM. To the best of our knowledge, this is the first meta-analysis to summarize previous relevant studies and further evaluate the clinical efficacy and safety of radical lymphadenectomy in targeted patients. In 2016, Wong et al. [
14] conducted a similar systematic review that included 18 studies and found that PALN dissection for isolated PALNM from CRC may confer a survival advantage in these patients. However, this study only analyzed the prognostic outcomes qualitatively and lacked quantitative results. As a result, the heterogeneity of included studies could not be eliminated.
Two studies included in this meta-analysis were cohort studies, and one was conducted by Lee [
20], which included 263 patients with left colon or rectal cancer who underwent para-aortic lymph node dissection (PALND). A total of 19 (7.2%) patients with PALNM confirmed by routine postoperative pathology, of whom 9 underwent R0 resection and 10 underwent R2 resection. The survival analysis showed that patients who underwent R0 resection had a significantly longer 5-year OS than the control group (90.0%
vs. 0.0%; P = 0.014). Another cohort study [
21] included in this analysis enrolled 28 patients with pathologically confirmed PALNM from a cohort of 2910 patients with primary colorectal cancer. The researchers chose 3-year RFS as the primary endpoint and reached a similar conclusion that radical lymphadenectomy could improve survival outcomes of CRC patients with PALNM.
Lymph node (LN) metastasis is an important prognostic factor of CRC [
22]. At present, several surgical methods have been developed to improve the survival rate of CRC patients and radical lymph node dissection is a very representative one, which has been the standard management for CRC surgery. Complete resection of metastatic tumors in CRC patients is known to improve survival and aggressive surgical approaches are advocated for specific patients with respectable liver and/or lung metastases [
3]. However, the optimal treatment for CRC with PALNM has not been clearly defined. Although PALNM was classified as stage III in previous version, the JSCCR updated it as stage IV in the latest version of the guidelines. This shift also indicated that the medical community was constantly perfecting its views and treatment strategies of PALNM [
6,
7]. Considering the discrepancies of PALNM disposal schemes in various countries, we therefore conducted a subgroup analysis according to the publishing nations. Three studies from Japan were included in the analysis, 2 of which were published before the latest edition of the guidelines was promulgated. However, the results showed no significant heterogeneity within the group (OR:5.34; 95% CI:1.48 − 19.25; P = 0.79; I
2 = 0%) and also did not affect the final conclusion of our study.
Simultaneous and metachronous CRC metastases usually exhibit diverse biological characteristics, as reported in previous studies [
23,
24]. Simultaneous metastases usually have a more aggressive clinical course and the prognosis is worse than that of metachronous metastases [
25,
26]. As for the location of colon tumors, numerous studies have also confirmed that there are significant differences in the pathological features and patients’ prognosis between left-sided colon cancers and right-sided ones [
4,
27,
28]. Therefore, subgroup analyses were accordingly performed based on the timing of metastasis and primary site of tumors. As a result, no significant heterogeneity was observed between and within groups, indicating that the conclusions we achieved had great consistency and stability.
Limitations
However, several limitations may exist in this systematic review and meta-analysis. First, all the studies included in the analysis were retrospective studies, and no relevant RCTS had been published by the time of screening. As the study type with the highest level of evidence in evidence-based medicine, the lack of RCTs will inevitably affect the reliability of our research conclusions. Second, the final eligible studies were all conducted in Japan or South Korea. As a global disease, CRC urgently needs joint efforts of scholars worldwide to provide more research data and strive to improve the prognosis of CRC patients with PALNM. Next, the managements in the control groups were also uneven, ranging from surveillance, systematic chemotherapy to R2 or R3 surgical resection, and all of which might become a confounding factor affecting the robustness of our conclusions. Moreover, several essential information like whether patients received neoadjuvant chemotherapy, detailed postoperative chemotherapy regimens and cycles were not mentioned in some studies. Finally, the clinical outcome indicators of included studies were relatively few. In addition to the primary outcome overall survival and incidence of postoperative adverse reactions, other secondary endpoints reflecting long-term survival of patients, such as tumor-free survival, relapse-free survival and tumor recurrence rate, were not recorded. Comprehensive analysis of these outcome indicators may be more accurate and reasonable for evaluating the survival benefit of patients.
Conclusion
Considering the lack of RCTs in CRC with PALNM research field, small sample size and insufficient demonstration level of retrospective clinical studies, we conducted the first meta-analysis in this field, hoping to provide some reference for gastrointestinal surgeons. The radical lymphadenectomy treatment has showed the expected clinical efficacy in improving overall survival of CRC patients with PALNM. Moreover, the preemptive radical lymphadenectomy could not cause additional postoperative complications.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.